Rigetti Turned $10,000 Into Over $81,000 in 3 Years -- and It's Still 73% Off Its High. Here's Why I Still Wouldn't Touch It.

Rigetti reported just $5.1 million of second-quarter revenue against a $28.1 million operating loss and used $32 million of operating cash in the first six months, underscoring its early-stage and cash-burning profile. Despite falling 73% from its peak, the quantum-computing company retains a market value above $5 billion and trades at more than 375x sales. Its $541 million cash and short-term investment balance, plus a Commerce Department letter of intent for up to $100 million over three years, provide funding support, but the article views the stock's volatility and valuation as unattractive.

Analysis

RGTI remains a duration-sensitive, narrative-led asset rather than a fundamentals-led technology exposure. Its cash balance reduces near-term financing risk, but also means the equity is effectively valuing a highly uncertain commercialization option at a large premium to both current revenue and likely several-year revenue capacity. The relevant downside catalyst is not another weak quarter—losses are expected—but evidence that customer bookings, paid quantum-cloud usage, or hardware performance milestones fail to convert into contracted demand over the next 1-3 quarters.

The proposed government support should be discounted until definitive award terms, matching requirements, milestone conditions, and timing are disclosed. Non-dilutive funding can extend runway, but it does not establish product-market fit; indeed, sector funding headlines may temporarily raise peer valuations without improving the competitive position versus better-capitalized quantum platforms such as IBM, Alphabet, IonQ (IONQ), and D-Wave (QBTS). A broad risk-off move in high-duration technology, rising real yields, or a delay in quantum error-correction progress would likely produce sharper downside in RGTI than in NVDA, whose valuation is supported by current AI infrastructure demand.

Consensus may be too focused on headline revenue multiples and too little on dilution-adjusted optionality. The stock can remain expensive on sales for years if it achieves credible technical milestones and capital markets stay open; therefore, an outright short has unfavorable squeeze risk after a 73% drawdown from peak. The cleaner expression is relative: RGTI underperformance versus IONQ or a diversified semiconductor/AI basket if milestone execution remains ambiguous, while avoiding a blanket short of quantum computing into government-funding momentum.

Key Decisions for Investors

• No outright long in RGTI before independently verifiable evidence of backlog conversion: require at least two consecutive quarters of material bookings/revenue acceleration or disclosed commercial contracts before reassessing.
• For a 1-3 month tactical bearish view, use a defined-risk RGTI put spread rather than short stock; size modestly because sector headlines and low-float momentum can generate discontinuous rallies. Exit if definitive federal funding terms are executed with accelerated cash receipts or if management raises commercial guidance.
• Consider a relative-value pair: short RGTI / long IONQ in equal dollar amounts over 3-6 months only after confirming comparable beta and borrow availability. Thesis is that RGTI's valuation premium is more vulnerable if technical or customer milestones slip; stop out on sustained relative outperformance following benchmark-performance validation.
• Maintain core AI exposure through NVDA rather than substituting RGTI as a speculative AI proxy. NVDA is exposed to current capex cycles, whereas RGTI requires a multi-year commercialization inflection; this distinction matters if real yields rise or enterprise AI budgets tighten.
• Set an event alert for definitive Commerce Department award documentation, quarterly cash burn, share-count changes, and contract backlog. Any financing or materially higher operating cash use would weaken the runway narrative and create a more attractive bearish entry.